Shares of Moderna have declined for the fifth day in a row after reports that the manufacturer refused to disclose details of the pricing of its vaccine in low-income countries. According to current data, in Botswana, Thailand and Colombia, the cost of the company's vaccine is higher than in developed countries. As a result, the shares of Moderna have fallen by 18% over the week and are not going to stop yet. Last week, one of the company's shareholders sent a statement to the SEC demanding to disclose information regarding whether Moderna takes into account the receipt of state financial support for the development and production of a vaccine against Covid-19 when forming the price. According to the company, Moderna has received almost $2.5 billion from various government agencies. In response, representatives of the company said that the manufacturer had already provided shareholders with information about the prices of vaccines for the US government, as well as general pricing principles. Despite this, the company's shares fell another 3% to $242.39 on Monday.
